| Literature DB >> 34772509 |
Fahad Humayun1, Abbas Khan2, Sajjad Ahmad3, Wang Yuchen4, Guoshen Wei5, N Nizam-Uddin6, Zahid Hussain7, Wajid Khan7, Nasib Zaman7, Muhammad Rizwan7, Muhammad Waseem8, Dong-Qing Wei9.
Abstract
The evolution of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants around the globe has made the coronavirus disease 2019 (COVID-19) pandemic more worrisome, pressuring the health care system and resulting in an increased mortality rate. Recent studies recognized neuropilin-1 (NRP1) as a key facilitator in the invasion of the new SARS-CoV-2 into the host cell. Therefore, it is considered an imperative drug target for the treatment of COVID-19. Hence, a thorough analysis was needed to understand the impact and to guide new therapeutics development. In this study, we used structural and biomolecular simulation techniques to identify novel marine natural products which could block this receptor and stop the virus entry. We discovered that the binding affinity of CMNPD10175, CMNPD10017, CMNPD10114, CMNPD10115, CMNPD10020. CMNPD10018, CMNPD10153, CMNPD10149 CMNPD10464 and CMNPD10019 were substantial during the virtual screening (VS). We further explored these compounds by analyzing their absorption, distribution, metabolism, and excretion and toxicity (ADMET) properties and structural-dynamics features. Free energy calculations further established that all the compounds exhibit stronger binding energy for NRP1. Consequently, we hypothesized that these compounds might be the best lead candidates for therapeutic interventions hindering virus binding to the host cell. This study provides a strong impetus to develop novel drugs against the SARS-CoV-2 by targeting NRP1.Entities:
Keywords: Biophysical simulation; KD. (dissociation constant); Marine natural products; NRP1; SARS-CoV-2; Virtual drugs screening
Mesh:
Substances:
Year: 2021 PMID: 34772509 PMCID: PMC8324387 DOI: 10.1016/j.compbiomed.2021.104714
Source DB: PubMed Journal: Comput Biol Med ISSN: 0010-4825 Impact factor: 6.698
Different drug-like parameters used in CMNP filtration.
| Parameters | Value |
|---|---|
| Molecular weight | 100–600 |
| logP | −3 to 6 |
| Hydrogen bond acceptor | ≤12 |
| Hydrogen bond donors | ≤7 |
| tPSA | ≤180 |
| Rotatable Bonds | ≤11 |
| Rigid Bonds | ≤3 |
| Rings | ≤6 |
| Max size system ring | ≤18 |
| Carbons | 3–35 |
| HeteroAtoms | 1–15 |
| H/C Ratio | 0.1 to 1.1 |
| Charges | ≤4 |
| TotalCharge | −4 to 4 |
| RO5 Violations | No |
Top ten marine drug compounds shortlisted through VS and applied drug-like filters. The docking score of each compound is given in kcal/mol.
| Compound ID | Compound Names | drug like | Lead likeness | Toxicity | Pharmacokinetics | Solubility | Score |
|---|---|---|---|---|---|---|---|
| CMNPD10175 | Madangolide | Yes | Yes | No | Good | Good | −8.0 |
| CMNPD10017 | Isogranulatimide | Yes | Yes | No | Good | Good | −6.9 |
| CMNPD10114 | Luisol B | Yes | Yes | No | Good | Good | −6.9 |
| CMNPD10115 | Luisol A | Yes | Yes | No | Good | Good | −6.8 |
| CMNPD10020 | Meridianin A | Yes | Yes | No | Good | Good | −6.6 |
Fig. 12D structure representation of the top five hits along with their CMNPD. database accession ID and original scientific names are given. The structural scaffold of all the compounds seems very similar, which reflects the same activity of these compounds.
Fig. 2Binding modes of Madangolide (CMNPD10175) (a) and Isogranulatimide (CMNPD10017) (b). The hydrogen-bonding interactions are shown in green colour, while the pie-alkyl interactions are shown as pink.
Fig. 3Binding modes of Luisol B (CMNPD10114) (a) and Luisol A (CMNPD10115) (b). The hydrogen bonding interactions are shown in green colour while the pie-alkyl interactions are shown as pink.
Fig. 4Binding modes of Meridianin A (CMNPD10020). The hydrogen-bonding interactions are shown in green colour, while the pie-alkyl interactions are shown as pink.
Top five marine drug compounds shortlisted through VS and drug-like rules. The docking score of each compound is given in kcal/mol.
| Compound ID | GPCR ligand | Ion Channels | Kinase Inhibitors | Nuclear Receptor ligand | Protease inhibitor | Enzymes inhibitor | Prodigy score |
|---|---|---|---|---|---|---|---|
| CMNPD10175 | 0.18 | −0.06 | −0.42 | 0.34 | 0.28 | 0.21 | −7.9 |
| CMNPD10017 | −0.07 | −0.10 | 1.29 | 0.64 | −0.20 | 0.41 | −7.3 |
| CMNPD10114 | 0.25 | 0.17 | −0.10 | 0.50 | 0.21 | 0.51 | −7.3 |
| CMNPD10115 | −0.04 | 0.01 | −0.20 | 0.46 | −0.11 | 0.34 | −7.3 |
| CMNPD10020 | 0.20 | 0.34 | 1.0 | 0.04 | −0.46 | 0.60 | −7.1 |
Fig. 5Thermodynamics stability calculated as RMSD of all the complexes. (a) CMNPD10175, (b) CMNPD1017, (c) CMNPD10114, (d) CMNPD10115 and (e) CMNPD10020 represent each complex.
Fig. 6Residual flexibility calculated as RMSF of all the complexes. All the complexes CMNPD10175, CMNPD1017, CMNPD10114, CMNPD10115 and CMNPD10020 represented with different colour.
Fig. 7Thermodynamics stability calculated as RMSD of all the complexes. (a) CMNPD10175, (b) CMNPD1017, (c) CMNPD10114, (d) CMNPD10115 and (e) CMNPD10020 represent each complex.
Binding free energy results of all the complexes calculated using the MM-GBSA approach. The free score of each compound is given against it in kcal/mol.
| Complex | vdW | Electrostatic | GB | ESURF | Total |
|---|---|---|---|---|---|
| −30.97 | −25.60 | 16.78 | −3.29 | ||
| −27.00 | −18.17 | 7.08 | −2.59 | ||
| −24.65 | −93.53 | 89.10 | −3.30 | ||
| −20.76 | −140.92 | 131.88 | −2.99 | ||
| −27.93 | −11.65 | 4.83 | −3.00 |